NASDAQ : BLTE

Belite Bio, Inc — Company profile

Healthcare · Biotechnology · United States

Last price 150.28 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.05B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Details

NameBelite Bio, Inc
SectorHealthcare
IndustryBiotechnology
Employees41
Founded2018
Ipo Date2022-04-29
CeoYu-Hsin Lin
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price6.00
IsinUS07782B1044
Cusip07782B104
Cik1889109
Sic2834

Key executives

NameTitle
Dr. Yu-Hsin Lin M.B.A., Ph.D.Chairman of the Board of Directors and Chief Executive Officer
Hao-Yuan Chuang C.F.A., F.R.M., M.B.A.Chief Financial Officer and Director
Dr. Nathan L. Mata Ph.D.Chief Scientific Officer
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D.Chief Medical Officer
Kelly KilpatrickChief Commercial Officer

Contact

Address12750 High Bluff Drive, Suite 475, San Diego, California 92130, United States
Phone858 246 6240
Websitehttps://www.belitebio.com